Bart Barlogie
University of Texas at Austin
7 Papers
88 Citations
Bart Barlogie is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Multiple myeloma & Messenger RNA. The author has an hindex of 6, co-authored 7 publications. Previous affiliations of Bart Barlogie include Temple University.
Chat about Author
Papers
Plasma Cell Karyotype in Multiple Myeloma
TL;DR: The association of all t(8;14) abnormalities with IgA protein type suggested a pathogenetic relationship between a specific karyotypic abnormality and myeloma protein type.
181
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia
Hagop M. Kantarjian,Ronald S. Walters,Terry L. Smith,Michael J. Keating,Bart Barlogie,Kenneth B. McCredie,Emil J. Freireich +6 more
TL;DR: The use of systemic chemotherapy containing multiple agents with good CNS penetration and in high doses (VAD regimen) in 90 patients was associated with a trend for lower CNS leukemia at 1 year, especially in the low-risk category.
85
A morphologic, immunologic, and cytometric approach to the classification of non-Hodgkin's lymphoma in effusions.
TL;DR: Correlation of the cytometric and morphologic data demonstrated that with increasing cytologic grade of lymphoma, the proliferative activity increased progressively and distinguished between grades, which can be readily performed on effusion specimens and aid in the diagnosis and classification of lymphomas.
58
HLA-DR-associated invariant chain is highly expressed in chronic lymphocytic leukemia.
Franco Narni,Franco Narni,Jiro Kudo,Jiro Kudo,Wendy Mars,Wendy Mars,Bruno Calabretta,Bruno Calabretta,Dagne L. Florine,Dagne L. Florine,Bart Barlogie,Bart Barlogie,Grady F. Saunders,Grady F. Saunders +13 more
TL;DR: A relationship between high levels of invariant chain mRNA and the out of cycle condition of CLL peripheral blood lymphocytes is supported and a role of In-chain mRNA as a marker of C LL is proposed.
25
Acridine-orange flow cytometry of urinary bladder washings for the detection of transitional cell carcinoma of the bladder. The influence of prior local therapy.
TL;DR: Analysis of cellular DNA and RNA contents of 249 bladder irrigation specimens from 129 patients with a history of transitional cell carcinoma of the bladder was performed using acridine‐orange flow cytometry (FCM), demonstrating the unreliability of FCM diploid and tetraploid cell populations in patients previously treated by local chemotherapy or radiation.
13